NCT01673009View on ClinicalTrials.gov

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

December 31, 2011

Study Completion Date

August 31, 2012

Conditions
Neurofibromatosis
Interventions
DRUG

Gleevec

Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.

Trial Locations (1)

46202

Indiana University, Indianapolis

All Listed Sponsors
lead

Indiana University

OTHER

NCT01673009 - Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas | Biotech Hunter | Biotech Hunter